Medical device firms say FDA scrutiny excessive
Late last year, Biosensors International, a medical device company, shut down its operation in Southern California, which had once housed 90 people, including the company's top executives and researchers. he reason, executives say, was that it would take too long to get its new cardiac stent approved by the Food and Drug Administration. "It's available all over the world, including Mexico and Canada, but not in the United States," said the chief executive, Jeffrey B. Jump, an American who runs the company from Switzerland. "We decided, let's spend our money in China, Brazil, India, Europe." Medical device industry executives and investors are complaining vociferously these days that the industry's competitive edge in the United States and overseas is being jeopardized by a heightened regulatory scrutiny.
- Anthem Blue Cross, 7 CA Health Systems Create New Challenger, Business Model
- EHR Systems 'Immature, Costly,' AMA Says
- Data Points to Boom in Private HIX
- Few Winners Among MSSP Participants
- Technology Lights Up Health Innovation Forum
- Interstate Medical Licensure Effort Advances
- Malnourishment 'Epidemic' Plagues Hospitals? Really?
- Hospitals and doctors fail patients by passing the buck on insurance rules
- How to Build a Health Plan from Scratch
- Better HCAHPS Scores Protect Revenue